Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Mar;108(3):669–677. doi: 10.1111/j.1476-5381.1993.tb12859.x

Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors.

G P Luscombe 1, K F Martin 1, L J Hutchins 1, J Gosden 1, D J Heal 1
PMCID: PMC1908013  PMID: 8467355

Abstract

1. The 5-hydroxytryptamine (5-HT)1A agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) has been evaluated in a mouse model for detecting potential antidepressants (Porsolt test). The effects of various receptor antagonists, lesions of brain monoaminergic neurones and chronic drug treatments on this 8-OH-DPAT-induced response have also been determined. 2. 8-OH-DPAT (0.3-10.0 mg kg-1, s.c.) dose-dependently increased the mobility of mice in the Porsolt test. Other selective 5-HT1A receptor ligands (0.3-30 mg kg-1, s.c.) either mimicked the 8-OH-DPAT response (ipsapirone, at 10 and 30 mg kg-1, s.c.) or were inactive (buspirone and gepirone). However, each of these compounds (< or = 100 mg kg-1, p.o.) inhibited the response to 8-OH-DPAT (3 mg kg-1, s.c.) when given concurrently. 3. The putative 5-HT1A antagonists, spiroxatrine (1-30 mg kg-1, p.o.), (+/-)-pindolol (30 mg kg-1, p.o.) and methiothepin (3-10 mg kg-1, p.o.), each attenuated the 8-OH-DPAT (3 mg kg-1, s.c.)-induced increase in mobility. 4. The dopamine D1 receptor antagonist, SCH 23390 (3-10 mg kg-1, p.o.), weakly reversed the 8-OH-DPAT response.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ablad B., Borg K. O., Carlsson E., EK L., Johnson G., Malmfors T., Regårdh C. G. A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):7–23. doi: 10.1111/j.1600-0773.1975.tb03318.x. [DOI] [PubMed] [Google Scholar]
  2. Bilski A. J., Halliday S. E., Fitzgerald J. D., Wale J. L. The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol. 1983 May-Jun;5(3):430–437. doi: 10.1097/00005344-198305000-00013. [DOI] [PubMed] [Google Scholar]
  3. Cervo L., Grignaschi G., Samanin R. 8-Hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist, reduces the immobility of rats in the forced swimming test by acting on the nucleus raphe dorsalis. Eur J Pharmacol. 1988 Dec 6;158(1-2):53–59. doi: 10.1016/0014-2999(88)90252-x. [DOI] [PubMed] [Google Scholar]
  4. Cervo L., Samanin R. Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist. Eur J Pharmacol. 1987 Dec 1;144(2):223–229. doi: 10.1016/0014-2999(87)90523-1. [DOI] [PubMed] [Google Scholar]
  5. Chojnacka-Wójcik E., Tatarczyńska E., Gołembiowska K., Przegaliński E. Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology. 1991 Jul;30(7):711–717. doi: 10.1016/0028-3908(91)90178-e. [DOI] [PubMed] [Google Scholar]
  6. Costall B., Naylor R. J. Dopamine antagonistic effects of a series of analogues of oxiperomide and spiroxatrine measured behaviourally in the rodent. J Pharm Pharmacol. 1978 Nov;30(11):693–698. doi: 10.1111/j.2042-7158.1978.tb13367.x. [DOI] [PubMed] [Google Scholar]
  7. Cott J. M., Kurtz N. M., Robinson D. S., Lancaster S. P., Copp J. E. A 5-HT1A ligand with both antidepressant and anxiolytic properties. Psychopharmacol Bull. 1988;24(1):164–167. [PubMed] [Google Scholar]
  8. Crespi F., Garratt J. C., Sleight A. J., Marsden C. A. In vivo evidence that 5-hydroxytryptamine (5-HT) neuronal firing and release are not necessarily correlated with 5-HT metabolism. Neuroscience. 1990;35(1):139–144. doi: 10.1016/0306-4522(90)90128-q. [DOI] [PubMed] [Google Scholar]
  9. De Souza R. J., Goodwin G. M., Green A. R., Heal D. J. Effect of chronic treatment with 5-HT1 agonist (8-OH-DPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists. Br J Pharmacol. 1986 Oct;89(2):377–384. doi: 10.1111/j.1476-5381.1986.tb10270.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dourish C. T., Hutson P. H., Curzon G. Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology (Berl) 1985;86(1-2):197–204. doi: 10.1007/BF00431709. [DOI] [PubMed] [Google Scholar]
  11. Doxey J. C., Roach A. G., Smith C. F. Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors. Br J Pharmacol. 1983 Mar;78(3):489–505. doi: 10.1111/j.1476-5381.1983.tb08809.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fabre L. F. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry. 1990 Sep;51 (Suppl):55–61. [PubMed] [Google Scholar]
  13. Fozard J. R., Mir A. K., Middlemiss D. N. Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol. 1987 Mar;9(3):328–347. doi: 10.1097/00005344-198703000-00010. [DOI] [PubMed] [Google Scholar]
  14. Gilbert F., Dourish C. T. Effects of the novel anxiolytics gepirone, buspirone and ipsapirone on free feeding and on feeding induced by 8-OH-DPAT. Psychopharmacology (Berl) 1987;93(3):349–352. doi: 10.1007/BF00187255. [DOI] [PubMed] [Google Scholar]
  15. Giral P., Martin P., Soubrié P., Simon P. Reversal of helpless behavior in rats by putative 5-HT1A agonists. Biol Psychiatry. 1988 Feb 1;23(3):237–242. doi: 10.1016/0006-3223(88)90034-0. [DOI] [PubMed] [Google Scholar]
  16. Goldberg H. L., Finnerty R. J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry. 1979 Sep;136(9):1184–1187. doi: 10.1176/ajp.136.9.1184. [DOI] [PubMed] [Google Scholar]
  17. Goodwin G. M., De Souza R. J., Green A. R., Heal D. J. The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Psychopharmacology (Berl) 1987;91(4):506–511. doi: 10.1007/BF00216019. [DOI] [PubMed] [Google Scholar]
  18. Goodwin G. M., De Souza R. J., Green A. R. Presynaptic serotonin receptor-mediated response in mice attenuated by antidepressant drugs and electroconvulsive shock. Nature. 1985 Oct 10;317(6037):531–533. doi: 10.1038/317531a0. [DOI] [PubMed] [Google Scholar]
  19. Goodwin G. M., De Souza R. J., Green A. R. The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology. 1985 Dec;24(12):1187–1194. doi: 10.1016/0028-3908(85)90153-4. [DOI] [PubMed] [Google Scholar]
  20. Goodwin G. M., Green A. R. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol. 1985 Mar;84(3):743–753. doi: 10.1111/j.1476-5381.1985.tb16157.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Green A. R., Goodwin G. M., De Souza R. J., Heal D. J. The beta 2-adrenoceptor agonists clenbuterol and salbutamol enhance the hypothermic action of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice by a central mechanism. Neuropharmacology. 1986 Jan;25(1):21–24. doi: 10.1016/0028-3908(86)90053-5. [DOI] [PubMed] [Google Scholar]
  22. Hamid-Bloomfield S., Whittle B. J. Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C. Br J Pharmacol. 1989 Feb;96(2):307–312. doi: 10.1111/j.1476-5381.1989.tb11818.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Heal D. J. Phenylephrine-induced activity in mice as a model of central alpha 1-adrenoceptor function. Effects of acute and repeated administration of antidepressant drugs and electroconvulsive shock. Neuropharmacology. 1984 Nov;23(11):1241–1251. doi: 10.1016/0028-3908(84)90040-6. [DOI] [PubMed] [Google Scholar]
  24. Heal D. J., Philpot J., Molyneux S. G., Metz A. Intracerebroventricular administration of 5,7-dihydroxytryptamine to mice increases both head-twitch response and the number of cortical 5-HT2 receptors. Neuropharmacology. 1985 Dec;24(12):1201–1205. doi: 10.1016/0028-3908(85)90155-8. [DOI] [PubMed] [Google Scholar]
  25. Hibert M., Middlemiss D. N. Stereoselective blockade at the 5-HT autoreceptor and inhibition of radioligand binding to central 5-HT recognition sites by the optical isomers of methiothepin. Neuropharmacology. 1986 Jan;25(1):1–4. doi: 10.1016/0028-3908(86)90050-x. [DOI] [PubMed] [Google Scholar]
  26. Hjorth S. Hypothermia in the rat induced by the potent serotoninergic agent 8-OH-DPAT. J Neural Transm. 1985;61(1-2):131–135. doi: 10.1007/BF01253058. [DOI] [PubMed] [Google Scholar]
  27. Hoyer D., Engel G., Kalkman H. O. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol. 1985 Nov 26;118(1-2):13–23. doi: 10.1016/0014-2999(85)90658-2. [DOI] [PubMed] [Google Scholar]
  28. Hutson P. H., Dourish C. T., Curzon G. Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A receptors. Eur J Pharmacol. 1988 Jun 10;150(3):361–366. doi: 10.1016/0014-2999(88)90019-2. [DOI] [PubMed] [Google Scholar]
  29. Kennett G. A., Dourish C. T., Curzon G. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol. 1987 Feb 24;134(3):265–274. doi: 10.1016/0014-2999(87)90357-8. [DOI] [PubMed] [Google Scholar]
  30. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  31. Leysen J., Tollenaere J. P., Koch M. H., Laduron P. Differentiation of opiate and neuroleptic receptor binding in rat brain. Eur J Pharmacol. 1977 Jun 1;43(3):253–267. doi: 10.1016/0014-2999(77)90025-5. [DOI] [PubMed] [Google Scholar]
  32. Marsden C. A., Martin K. F. Involvement of 5-HT1A- and alpha 2-receptors in the decreased 5-hydroxytryptamine release and metabolism in rat suprachiasmatic nucleus after intravenous 8-hydroxy-2-(n-dipropylamino) tetralin. Br J Pharmacol. 1986 Oct;89(2):277–286. doi: 10.1111/j.1476-5381.1986.tb10257.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Martin K. F., Mason R. Isapirone is a partial agonist at 5-hydroxytryptamine 1A (5-HT1A) receptors in the rat hippocampus: electrophysiological evidence. Eur J Pharmacol. 1987 Sep 23;141(3):479–483. doi: 10.1016/0014-2999(87)90569-3. [DOI] [PubMed] [Google Scholar]
  34. Massingham R., Dubocovich M. L., Shepperson N. B., Langer S. Z. In vivo selectivity of prazosin but not of WB4101 for postsynaptic alpha-1 adrenoceptors. J Pharmacol Exp Ther. 1981 May;217(2):467–474. [PubMed] [Google Scholar]
  35. NIEMEGEERS C. J., VERBRUGGEN F. J., VANNUETEN J. M., JANSSEN P. A. SPIROXAMIDE (R 5188): A NEW COMPOUND PRODUCING MORPHINE-LIKE AND CHLORPROMAZINE-LIKE EFFECTS IN ANIMALS. Int J Neuropharmacol. 1963 Dec;2:349–354. doi: 10.1016/0028-3908(63)90010-8. [DOI] [PubMed] [Google Scholar]
  36. Nelson D. L., Taylor E. W. Spiroxatrine: a selective serotonin1A receptor antagonist. Eur J Pharmacol. 1986 May 13;124(1-2):207–208. doi: 10.1016/0014-2999(86)90147-0. [DOI] [PubMed] [Google Scholar]
  37. Peroutka S. J. 5-Hydroxytryptamine receptor subtypes. Annu Rev Neurosci. 1988;11:45–60. doi: 10.1146/annurev.ne.11.030188.000401. [DOI] [PubMed] [Google Scholar]
  38. Porsolt R. D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327–336. [PubMed] [Google Scholar]
  39. Robinson D. S., Rickels K., Feighner J., Fabre L. F., Jr, Gammans R. E., Shrotriya R. C., Alms D. R., Andary J. J., Messina M. E. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):67S–76S. doi: 10.1097/00004714-199006001-00013. [DOI] [PubMed] [Google Scholar]
  40. Smith L. M., Peroutka S. J. Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav. 1986 Jun;24(6):1513–1519. doi: 10.1016/0091-3057(86)90477-6. [DOI] [PubMed] [Google Scholar]
  41. Sprouse J. S., Aghajanian G. K. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987;1(1):3–9. doi: 10.1002/syn.890010103. [DOI] [PubMed] [Google Scholar]
  42. Tricklebank M. D., Forler C., Fozard J. R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol. 1984 Nov 13;106(2):271–282. doi: 10.1016/0014-2999(84)90714-3. [DOI] [PubMed] [Google Scholar]
  43. Wieland S., Lucki I. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology (Berl) 1990;101(4):497–504. doi: 10.1007/BF02244228. [DOI] [PubMed] [Google Scholar]
  44. Williams D. A. The comparison of several dose levels with a zero dose control. Biometrics. 1972 Jun;28(2):519–531. [PubMed] [Google Scholar]
  45. Yamada J., Sugimoto Y., Horisaka K. The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur J Pharmacol. 1988 Sep 23;154(3):299–304. doi: 10.1016/0014-2999(88)90205-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES